Home » Stocks » PRAX

Praxis Precision Medicines, Inc. (PRAX)

Stock Price: $27.62 USD 1.29 (4.90%)
Updated May 6, 2021 4:00 PM EDT - Market closed
Market Cap 984.89M
Revenue (ttm) n/a
Net Income (ttm) -70.32M
Shares Out 38.63M
EPS (ttm) -7.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $27.62
Previous Close $26.33
Change ($) 1.29
Change (%) 4.90%
Day's Open 26.42
Day's Range 25.90 - 28.00
Day's Volume 130,934
52-Week Range 23.90 - 60.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PRAX-562 Phase 2 clinical trial for treatment of DEEs expected to initiate in first half of 2022 PRAX-562 Phase 2 clinical trial for treatment of DEEs expected to initiate in first half of 2022

6 days ago - GlobeNewsWire

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ther...

1 week ago - GlobeNewsWire

CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ther...

3 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ther...

1 month ago - GlobeNewsWire

PRAX-114 Phase 2/3 clinical trial for treatment of MDD to initiate in March 2021 following IND clearance

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of thera...

5 months ago - GlobeNewsWire

- Praxis expects to initiate Phase 2/3 clinical trial for PRAX-114 in MDD in 1H21 -

5 months ago - GlobeNewsWire

NEW YORK, Nov. 11, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ("Praxis" or the "Company") (NASDAQ: PRAX). Such investors are ad...

5 months ago - PRNewsWire

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of thera...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of thera...

6 months ago - GlobeNewsWire

Nine IPOs and five SPACs went public this past week, and one IPO postponed.

Other stocks mentioned: ALGS, ARRY, CDAK, EBC, OPT, SPEL, TARS
6 months ago - Seeking Alpha

CAMBRIDGE, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of thera...

6 months ago - GlobeNewsWire

Praxis Precision Medicines Inc. has increased the number of shares it plans to sell in its initial public offering by 35%, as the Massachusetts-based biopharmaceutical company developing treatments for ...

6 months ago - Market Watch

Praxis Precision Medicines has filed proposed terms for its U.S. IPO.

6 months ago - Seeking Alpha

Praxis Precision Medicines Inc. set terms for its initial public offering, in which the Massachusetts-based biopharmaceutical company developing treatments for central nervous system disorders looks to ...

6 months ago - Market Watch

About PRAX

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential... [Read more...]

Industry
Biotechnology
IPO Date
Oct 16, 2020
Stock Exchange
NASDAQ
Ticker Symbol
PRAX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for PRAX stock is "Strong Buy." The 12-month stock price forecast is 66.00, which is an increase of 138.96% from the latest price.

Price Target
$66.00
(138.96% upside)
Analyst Consensus: Strong Buy